Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or ...
The results from both studies were presented in two poster presentations (abstracts PS2082 and PF1007) at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden, June 11-14.
SurvivorNet on MSN
For high-risk lymphoma, adding targeted drugs tafasitamab and lenalidomide to standard treatment keeps cancer away for longer
The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy ...
Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) may offer a meaningful advance for patients with newly diagnosed high-risk diffuse ...
Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy ...
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death1 People with relapsed ...
In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results